A new MDCK suspension line cultivated in a fully defined medium in stirred-tank and wave bioreactor

Vaccine

Volumn 28, Issue 38, 2010, Pages 6256-6264

  Lohr, V ^a   Genzel, Y ^a   Behrendt, I ^a   Scharfenberg, K ^b   Reichl, U ^a,c  

^a MAX PLANCK INSTITUTE FOR DYNAMICS OF COMPLEX TECHNICAL SYSTEMS   (Germany)

^b UNIVERSITY OF APPLIED SCIENCES EMDEN LEER   (Germany)

^c OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Chemically defined medium; Influenza virus; Suspension MDCK; Vaccine production; Wave bioreactor

Indexed keywords

INFLUENZA VACCINE;

ANIMAL CELL; ARTICLE; BIOREACTOR; CELL STRAIN; CULTURE MEDIUM; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS B; NONHUMAN; PRIORITY JOURNAL; STIRRED REACTOR; VACCINE PRODUCTION; VIRUS CELL INTERACTION; VIRUS CULTURE; WAVE BIOREACTOR;

ANIMALS; BIOREACTORS; CELL LINE; CULTURE MEDIA; DOGS; ORTHOMYXOVIRIDAE; VIRUS CULTIVATION;

EID: 77955656086     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.07.004     Document Type: Article

References (48)

1. Ferreira T.B., Perdigao R., Silva A.C., Zhang C., Aunins J.G., Carrondo M.J., et al. 293 cell cycle synchronisation in adenovirus vector production. Biotechnol Prog 2009, 25(1):235-243.
2. Uytdehaag AGCM, Pau MG, Schouten G. Production influenza virus vaccines. WO 2007/045674 A1; 2007.
3. Mehtali M, Chamion-Arnaud P, Leon A. Process of manufacturing viral vaccines in suspension avian embryonic derived stem cell lines. WO 2006/108846 A1; 2006.
4. Sandig V, Jordan I. Immortalized avian cell lines for virus production. WO 2005/042728 A2; 2005.
5. Kistner O., Barrett P.N., Mundt W., Reiter M., Schober-Bendixen S., Dorner F. Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine 1998, 16(9-10):960-968.
6. Liu J., Shi X., Schwartz R., Kemble G. Use of MDCK cells for production of live attenuated influenza vaccine. Vaccine 2009, 27(46):6460-6463.
7. Merten O.W., Hannoun C., Manuguerra J.C., Ventre F., Petres S. Production of influenza virus in cell cultures for vaccine preparation. Adv Exp Med Biol 1996, 397:141-151.
8. Makizumi K., Kimachi K., Fukada K., Nishimura T., Kudo Y., Goto S., et al. Timely production of A/Fujian-like influenza vaccine matching the 2003-2004 epidemic strain may have been possible using Madin-Darby canine kidney cells. Vaccine 2008, 26(52):6852-6858.
9. Youil R., Su Q., Toner T.J., Szymkowiak C., Kwan W.S., Rubin B., et al. Comparative study of influenza virus replication in Vero and MDCK cell lines. J Virol Methods 2004, 120(1):23-31.
10. Halperin S.A., Smith B., Mabrouk T., Germain M., Trepanier P., Hassell T., et al. Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children. Vaccine 2002, 20(7-8):1240-1247.
11. Chu L., Robinson D.K. Industrial choices for protein production by large-scale cell culture. Curr Opin Biotechnol 2001, 12(2):180-187.
12. Animal cell technology-from biopharmaceuticals to gene therapy 2008, Taylor & Francis Group.
13. Durocher Y., Pham P.L., St-Laurent G., Jacob D., Cass B., Chahal P., et al. Scalable serum-free production of recombinant adeno-associated virus type 2 by transfection of 293 suspension cells. J Virol Methods 2007, 144(1-2):32-40.
14. Pay T.W. Production of rabies vaccine by an industrial scale BHK 21 suspension cell culture process. Dev Biol Stand 1985, 60:171-174.
15. Gröner A, Vorlop J. Animal cells and processes for the replication of influenza viruses. WO 97/37000; 1997.
16. Rappuoli R, O'Hagan D, Del Giudice G. Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture. WO 2007/052055 A1; 2007.
17. Doroshenko A., Halperin S.A. Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines). Expert Rev Vaccines 2009, 8(6):679-688.
18. Bjare U. Serum-free cell culture. Pharmacol Ther 1992, 53(3):355-374.
19. Merten O.W., Manuguerra J.C., Hannoun C., van der Werf S. Production of influenza virus in serum-free mammalian cell cultures. Dev Biol Stand 1999, 98:23-37. [discussion 73-74].
20. Reiter M, Mundt W, Grillberger L, Kraus B. Animal protein free media for cultivation of cells. WO 2004/005493 A1; 2004.
21. Genzel Y., Fischer M., Reichl U. Serum-free influenza virus production avoiding washing steps and medium exchange in large-scale microcarrier culture. Vaccine 2006, 24(16):3261-3272.
22. Genzel Y., Behrendt I., König S., Sann H., Reichl U. Metabolism of MDCK cells during cell growth and influenza virus production in large-scale microcarrier culture. Vaccine 2004, 22(17-18):2202-2208.
23. Schulze-Horsel J., Genzel Y., Reichl U. Flow cytometric monitoring of influenza A virus infection in MDCK cells during vaccine production. BMC Biotechnol 2008, 8:45.
24. Lohr V., Rath A., Genzel Y., Jordan I., Sandig V., Reichl U. New avian suspension cell lines provide production of influenza virus and MVA in serum-free media: studies on growth, metabolism and virus propagation. Vaccine 2009, 27(36):4975-4982.
25. Genzel Y., König S., Reichl U. Amino acid analysis in mammalian cell culture media containing serum and high glucose concentrations by anion exchange chromatography and integrated pulsed amperometric detection. Anal Biochem 2004, 335(1):119-125.
26. Kalbfuss B., Knochlein A., Krober T., Reichl U. Monitoring influenza virus content in vaccine production: precise assays for the quantitation of hemagglutination and neuraminidase activity. Biologicals 2008, 36(3):145-161.
27. Mahy B.W.J., Kangro H.O. Virology methods manual 1996, Academic Press Limited.
28. Genzel Y., Reichl U. Vaccine production-state of the art and future needs in upstream processing. Animal cell biotechnology: methods and protocols 2007, 457-473. Humana Press Inc. R. Poertner (Ed.).
29. Ozturk S.S., Palsson B.O. Growth, metabolic, and antibody production kinetics of hybridoma cell culture. 1. Analysis of data from controlled batch reactors. Biotechnol Prog 1991, 7(6):471-480.
30. Genzel Y., Ritter J.B., König S., Alt R., Reichl U. Substitution of glutamine by pyruvate to reduce ammonia formation and growth inhibition of mammalian cells. Biotechnol Prog 2005, 21(1):58-69.
31. Scharfenberg K., Wagner R. A reliable strategy for the achievement of cell lines growing in protein-free medium. Animal cell technology: developments towards the 21st century 1995, 619-623. Kluwer Academic Publishers. E.C. Beuvery, W.P. Zeijlemaker, J.B. Griffiths (Eds.).
32. Liu J., Mani S., Schwartz R., Richman L., Tabor D.E. Cloning and assessment of tumorigenicity and oncogenicity of a Madin-Darby canine kidney (MDCK) cell line for influenza vaccine production. Vaccine 2010, 28(5):1285-1293.
33. Takaoka T., Katsuta H. Long-term cultivation of mammalian cell strains in protein- and lipid-free chemically defined synthetic media. Exp Cell Res 1971, 67(2):295-304.
34. Merten O.W., Kierulff J.V., Castignolles N., Perrin P. Evaluation of the new serum-free medium (MDSS2) for the production of different biologicals: use of various cell lines. Cytotechnology 1994, 14(1):47-59.
35. Tsai TF, Trusheim H. Making influenza virus vaccines without using eggs. WO 2008/032219 A2; 2008.
36. Schwartz R, Berry JM, Subramanian A, Shi X. Non-tumorigenic MDCK cell line for propagating viruses. WO 2006/071563 A2; 2006.
37. Reiter M, Mundt W. Method for large scale production of virus antigen. WO 2003/054174 A1; 2003.
38. Castle P., Robertson J.S. Summary and conclusion. Animal sera, animal sera derivatives and substitutes used in the manufacture of pharmaceuticals. Dev Biol Stand 1999, 99:191-196.
39. Wahl A., Sidorenko Y., Dauner M., Genzel Y., Reichl U. Metabolic flux model for an anchorage-dependent MDCK cell line: characteristic growth phases and minimum substrate consumption flux distribution. Biotechnol Bioeng 2008, 101(1):135-152.
40. Rourou S., van der Ark A., Majoul S., Trabelsi K., van der Velden T., Kallel H. A novel animal-component-free medium for rabies virus production in Vero cells grown on Cytodex 1 microcarriers in a stirred bioreactor. Appl Microbiol Biotechnol 2009, 85(1):51-63.
41. Glacken M.W., Fleischaker R.J., Sinskey A.J. Reduction of waste product excretion via nutrient control: possible strategies for maximizing product and cell yields on serum in cultures of mammalian cells. Biotechnol Bioeng 1986, 28(9):1376-1389.
42. Maranga L., Goochee C.F. Metabolism of PER.C6 cells cultivated under fed-batch conditions at low glucose and glutamine levels. Biotechnol Bioeng 2006, 94(1):139-150.
43. Pohlscheidt M., Langer U., Minuth T., Bodeker B., Apeler H., Horlein H.D., et al. Development and optimisation of a procedure for the production of Parapoxvirus ovis by large-scale microcarrier cell culture in a non-animal, non-human and non-plant-derived medium. Vaccine 2008, 26(12):1552-1565.
44. Ghani K., Garnier A., Coelho H., Transfiguracion J., Trudel P., Kamen A. Retroviral vector production using suspension-adapted 293GPG cells in a 3L acoustic filter-based perfusion bioreactor. Biotechnol Bioeng 2006, 95(4):653-660.
45. Genzel Y., Reichl U. Continuous cell lines as production system for influenza vaccines. Expert Rev Vaccines 2009, 8(12):1681-1692.
46. Schulze-Horsel J., Schulze M., Agalaridis G., Genzel Y., Reichl U. Infection dynamics and virus-induced apoptosis in cell culture-based influenza vaccine production-Flow cytometry and mathematical modeling. Vaccine 2009, 27(20):2712-2722.
47. Häggström L. Cell metabolism, animal. Encyclopedia of cell technology 2000, John Wiley & Sons, Inc. R.E. Spier (Ed.).
48. Janke R, Genzel Y, Wahl A, Reichl U. Measurement of key metabolic enzyme activities in mammalian cells using rapid and sensitive microplate-based assays. Biotech Bioeng 2010; doi:10.1002/bit.22817.